Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.



# **2017 FIRST QUARTERLY REPORT**

#### **1. IMPORTANT NOTICE**

- **1.1** The board of directors (the "Board"), the supervisory committee (the "Supervisory Committee") of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ("GYBYS" or the "Company") and its directors, supervisors and senior management collectively and individually accept full responsibility for the truthfullness, accuracy and completeness of the information contained in this quarterly report and confirm that there are no false information, misleading statements or material omissions in this quarterly report.
- **1.2** The directors of the Company (the "Directors") attended the 30th meeting of the sixth session of the Board, among whom, Mr. Li Chuyuan (chairperson of the Board) was unable to attend the meeting due to business reason and has appointed Mr. Chen Mao (vice chairperson of the Board) to attend the meeting and vote on his behalf. Ms. Liu Juyan (an executive Director) was unable to attend the meeting due to business reason and has appointed Mr. Wu Changhai (an executive Director) to attend the meeting and vote on her behalf. Ms. Cheng Ning (an executive Director) was unable to attend the meeting due to business reason and has appointed Mr. Wu Changhai (an executive Director) to attend the meeting due to business reason and has appointed Mr. Ni Yidong (an executive Director) to attend the meeting and vote on her behalf. Mr. Wong Lung Tak Patrick (an independent non-executive Director) attended the meeting by means of telephone. Mr. Qiu Hongzhong (an independent non-executive Director) was unable to attend the meeting due to bisiness reason and has appointed the meeting due to business reason and her behalf. Mr. Wong Lung Tak Patrick (an independent non-executive Director) attended the meeting by means of telephone. Mr. Qiu Hongzhong (an independent non-executive Director) was unable to attend the meeting due to business reason and has appointed the meeting due to business reason and has appointed the meeting due to business reason and has appointed the meeting due to business reason and has appointed Mr. Chu Xiaoping (an independent non-executive Director) to attend the meeting and vote on his behalf.
- **1.3** The financial reports of the Company and its subsidiaries (collectively, the "Group"), and the Company for the first quarter ended 31 March 2017 (the "Reporting Period") are prepared in accordance with the China Accounting Standards for Business Enterprises, which are unaudited.
- **1.4** Mr. Li Chuyuan (chairperson of the Board), Mr. Wu Changhai (an executive Director and deputy general manager) and Ms. Yao Zhizhi (deputy director of Finance and head of finance department) declared that they warranted that the financial reports contained in this quarterly report were true and complete.
- **1.5** This 2017 first quarterly report is published in Hong Kong pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules of HKEx") (the "HKEx") and Part XIVA of the Securities and Futures Ordinance (Cap. 571).
- **1.6** This quarterly report is prepared in both English and Chinese. In the event that different interpretation occurs, the Chinese version shall prevail.

# 2. BASIC INFORMATION ON THE COMPANY

# 2.1 Principal financial data

			Increase/ (Decrease) as
	As at	As at	compared with
	31 March	31 December	31 December
Items	2017	2016	2016
	(Unaudited)	(Audited)	(%)
Total assets ( <i>RMB'000</i> ) Net assets attributable to the shareholders	26,579,719	25,897,170	2.64
of the Company ( <i>RMB'000</i> )	17,832,555	17,345,080	2.81
Equity attributable to the shareholders of the Company per share ( <i>RMB</i> )	10.97	10.67	2.81
			Increase/ (Decrease) as compared with the corresponding
	1 January –	1 January –	period of
Items	31 March 2017	31 March 2016	2016
	(Unaudited)	(Unaudited)	(%)
Net cash flow from operating activities ( <i>RMB'000</i> )	225,970	743,266	(69.60)
Net cash flow from operating activities per share ( <i>RMB</i> )	0.14	0.58	(75.86)

			Increase/
			(Decrease)
			as compared
			with the
			corresponding
	1 January –	1 January –	period of
Items	31 March 2017	31 March 2016	2016
	(Unaudited)	(Unaudited)	(%)
Income from operations (RMB'000)	5,287,931	5,050,889	4.69
Net profit attributable to the shareholders			
of the Company (RMB'000)	484,662	409,319	18.41
Net profit attributable to the shareholders			
of the Company after deducting			
non-recurring items (RMB'000)	461,835	393,748	17.29
Basic earnings per share (RMB)	0.298	0.317	(5.99)
Diluted earnings per share (RMB)	0.298	0.317	(5.99)
Ratio of weighted average return	2.76	4.73	A decrease of
on net assets (%)			1.97 percentage
			ponits
Ratio of weighted average return	2.63	4.55	A decrease of
on net assets after deducting			1.92 percentage
non-recurring items (%)			ponits

Notes: (1) The above financial data and indicators are computed based on the consolidated financial statements.

(2) Non-recurring items include:

Items (1 January – 31 March 2017)	Amount (RMB'000)	Notes
Gain/(Loss) on disposal of non-current assets	(365)	
Government subsidies recognized as gain/(loss)	43,675	This is the amount of government subsidies received by the Company's subsidiaries which were transferred to non-operating income in the Reporting Period.
Gain/(Loss) on changes in fair value arising from trading financial assets and trading financial liabilities held (excluding the valid hedging business related to normal operating activities of the Company), as well as investment gains received from disposal of trading financial assets, trading financial liabilities and financial assets available for sale	(273)	
Write-off provision for impairment of accounts receivable undergoing independent impairment test	184	
Other non-operating income and expenses excluding the above items	(17,079)	
Income tax effect	(3,132)	
Effect on minority interest	(183)	
Total	22,827	

# 2.2 The total number of shareholders and the top ten shareholders of the Company as at the end of the Reporting Period (after completion of the Share Reform Plan):

As at 31 March 2017, the Company had 65,088 shareholders in total, among which, 65,061 shareholders held the Renminbi-denominated ordinary shares (A Shares) and 27 shareholders held overseas listed foreign shares (H Shares).

Shareholders	Number of shares held as at the end of the Reporting Period (share)	Approximate percentage of the total issued share capital (%)	Number of shares held which were subject to selling restrictions held (share)	Number of pledged or (shares	locked	<b>Class of shares</b> (share)
				status	shares (share)	
Guangzhou Pharmaceutical Holdings Company ("GPHL")	732,305,103	45.04	148,338,467	Pledged	172,390,000	Domestic shares
HKSCC Nominees Limited	219,605,469	13.51	Nil	Nil	0	H shares
Guangzhou State-owned Asset	87,976,539	5.41	87,976,539	Nil	0	Domestic shares
Development Holdings Limited						
Guangzhou China Life Urban Development Industry Investment Enterprise (Limited Partnership)	73,313,783	4.51	73,313,783	Nil	0	Domestic shares
China Securities Finance Corporation Limited	33,553,144	2.06	Nil	Nil	0	Domestic shares
Shanghai Yunfeng Xinchuang Equity Investment Center (Limited Partnership)	21,222,410	1.31	21,222,410	Nil	0	Domestic shares
Central Huijin Investment Limited	15,260,700	0.94	Nil	Nil	0	Domestic shares
The Industrial and Commercial Bank of China Co., Ltd. -Southern Consumption Vitality Flexibly Configured Mixed Initiate Securities Investment Funds	9,945,228	0.61	Nil	Nil	0	Domestic shares
The National Social Security Fund – One Two Combination	8,911,296	0.55	Nil	Nil	0	Domestic shares
Abu Dhabi Investment Authority	7,075,556	0.44	Nil	Nil	0	Domestic shares

# The top ten shareholders of the Company not subject to selling restrictions

Shareholders	Number of shares without selling restrictions (share)	Class of shares	<b>The number</b> <b>of shares</b> (share)
GPHL	538,966,636	Domestic shares	732,305,103
HKSCC Nominees Limited	219,605,469	H shares	219,605,469
China Securities Finance Corporation Limited		Domestic shares	33,553,144
Central Huijin Investment Limited	15,260,700	Domestic shares	15,260,700
The Industrial and Commercial Bank of China Co., Ltd. -Southern Consumption Vitality Flexibly Configured Mixed Initiate Securities Investment Funds	9,945,228	Domestic shares	9,945,228
The National Social Security Fund – 107 Combination	8,911,296	Domestic shares	8,911,296
Abu Dhabi Investment Authority	7.075.556	Domestic shares	7,075,556
New China Life Insurance Co., Ltd. - Dividend – Group Dividend -018L – FH001 Hu		Domestic shares	6,380,585
Bank of China Co., Ltd. – Huaxia New Economy Flexible Configuration of Mixed-type Securities Investment Fund	4,940,150	Domestic shares	4,940,150
Hong Kong Securities Clearing Company Limited	4,784,661	Domestic shares	4,784,661
Explanation on the connection or (1 parties acting in concert among the above shareholders	Nominees I	the information prov Limited, the H shares half of clients.	•
(2	among the they were p the "Rules Shareholder	was not aware of an above top ten shareh parties acting in conc Governing the Discle rs' Shareholding in I	olders, or whether cert as provided in osure of Change in
Explanation on the restoration of N voting rights of shareholder holding preferred shares and	il		

the number of shares held

2.3 The total number of shareholders holding preferred shares, the top ten shareholders holding preferred shares and the top ten shareholders holding preferred shares without selling restrictions as at the end of the Reporting Period

 $\Box$  Applicable  $\checkmark$  Not applicable

#### 3. MAJOR EVENTS

# **3.1** Significant changes in major accounting items and financial indicators of the Company's financial statements and reasons for changes

✓ Applicable  $\Box$  Not applicable

Items	As at 31 March 2017 ( <i>RMB'000</i> )	As at 31 December 2016 ( <i>RMB</i> '000)	Fluctuation (%)	Reasons for changes
Notes receivable	2,177,650	1,604,768	35.70	This is mainly due to the increase in bills of exchange received by the Group as a result of the tightened domestic money liquidity as at 31 March 2017.
Advances to suppliers	258,799	414,074	(37.50)	This is mainly due to the decrease in advance payment for purchasing raw materials and packaging materials by the Company's subsidiaries as at 31 March 2017.
Development costs	2,017	3,017	(33.14)	This is mainly due to the decrease in the ending balance of the Group's development expenses as at 31 March 2017.
Other non-current assets	0	35,970	(100.00)	The formalities for transfer of property rights of the assets purchased by the Company's subsidiaries have been completed as at 31 March 2017.
Notes payable	212,359	320,812	(33.81)	This is mainly due to the decrease in the amount of notes payable by the Group for the purchase of raw materials as at 31 March 2017.

Items	1 January – 31 March 2017 ( <i>RMB</i> '000)	1 January – 31 March 2016 ( <i>RMB</i> '000)	Fluctuation (%)	Reasons for changes
Financial expenses	(28,075)	(9,350)	(200.25)	This is mainly due to improvement in the Group's fund management, reduction in bank borrowings, increase in interest income and reduction in financial cost as a result of the Group's reasonable fund allocation, increase in investment financing as well as optimization in types of deposit during the Reporting Period.
Asset impairment losses	(3,038)	5,101	(159.55)	This is mainly due to the decrease in the impairment loss recognized by the Group during the Reporting Period.
Profit arising from the changes in fair value	(273)	(1,013)	72.99	This is mainly due to the rise in AVIC HAIG and Harbin Pharmaceutical Group share prices held by the Company during the Reporting Period.
Non-operating income	46,573	35,678	30.54	This is mainly due to the increase in government compensation recognized by the Company's subsidiaries during the Reporting Period.
Non-operating expenses	20,343	15,458	31.60	This is mainly due to the compensation for breach of contract of the Company's subsidiary during the Reporting Period.
Net cash flows from operating activities	225,970	743,266	(69.60)	This is mainly due to the government compensation for land relocation received by the Company's subsidiaries in the same period of last year, which did not occur during the Reporting Period.
Net cash flows from investing activities	(13,275)	(105,063)	87.36	This is mainly due to decrease in the funds paid for production sites, equipment and investment projects of the Group and receiving dividend payout of investment enterprises during the Reporting Period.
Net cash flows from financing activities	1,691	(50,559)	103.35	This is mainly due to decrease in bank borrowings as compared with the corresponding period as the Group repaid its banks loans during the Reporting Period.

#### 3.2 Explanation and analysis on major events and their impact and solutions

 $\Box$  Applicable  $\checkmark$  Not applicable

# 3.3 Performance of the undertakings by the Company, its shareholders and its beneficial owner

✓ Applicable □ Not applicable

#### 3.3.1 Equity incentive implemented by listed company

Item	Content
Background of undertaking	Undertakings in connection with equity division reform
Party given the undertaking	Controlling shareholder
Details of the undertaking	1. In order to improve the value of the listed company, after completion of the reform, the controlling shareholder of the Company, GPHL will, to the extent permitted by laws and regulations and subject to the approval of the supervisory authority, support the Company to set up an equity incentive mechanism as the prerequisite for management to fulfill their rights of options based on the performance growth of the listed company.
	2. Upon the original undertakings, GPHL made further undertaking: In order to fully mobilize the initiative and creativity of the management team of the listed company, realize the sustainable development and improve the value of the listed company, GPHL undertakes that it will, to the extent permitted by laws and regulations and subject to the approvals of the supervisory authorities, urge and support the Company to set up incentive scheme for medium to long term within three years from the date of this undertaking letter, which scheme shall stipulate the growth in profits of the Company as a condition and link to market value.
Time and period of undertaking	The original undertaking was given in March 2006. On 25 June 2014, GPHL supplemented the original undertaking. The undertaking remains valid until it has been fully performed.
Valid period for performance	In order to improve the incentive mechanism, the Company implemented the Employee Stock Ownership Scheme (2015), completion of which occurred on 17 August 2016.
Whether strictly and timely performed	Fully performed
Compliance or not	Yes

Item	Content
Background of undertakings	Undertakings related to Major Assets Reorganization
Party given the undertaking	Controlling shareholder
Details of the undertaking	<ol> <li>After completion of the Major Assets Reorganization, GPHL, the controlling shareholder of the Company, will comply with the requirements of relevant laws and regulations, regulatory documents and the Articles of Association of the Company, and exercise shareholder's right according to laws and will not affect the independence of the Company by exerting its influence as a controlling shareholder and will maintain the integrity and independence of the Company in respect of assets, employees, finance, organisation and business.</li> <li>The undertaking letter will remain effective so long as GPC legally and validly exists and GPHL owns controlling interest in the Company.</li> </ol>
Time and period of the	The undertaking was given on 29 February 2012 and
undertaking	is valid permanently.
Valid period for performance	N/A
Whether timely and strictly performed	Being performed
Compliance or not	Yes

Item	Content
Background of undertakings	Undertakings related to the Major Assets Reorganization
Party given the undertaking	Controlling shareholder
Details of the undertaking	<ol> <li>After completion of the Major Assets Reorganization, GPHL and its controlled subsidiaries should avoid engaging in business and operations which substantially compete with those of the subsisting the Company after completion of the Major Assets Reorganization ("new GPC"), and avoid increasing investment in companies and enterprises, other than new GPC and its subsidiaries, which engages in business and operations which substantially compete with those of new GPC. GPHL will not and will procure its subsidiaries not to engage in the same or similar business of new GPC to avoid direct or indirect competition with the operation and business of new GPC. In addition, GPHL will voluntarily and vigorously procure its subsidiaries to give up competition with new GPC if GPHL and its subsidiaries will bring unfair impact on new GPC in respect of market shares, business opportunities and allocation of resources.</li> <li>GPHL shall bear the economic losses and/or additional costs directly and/or indirectly suffered or incurred by new GPC due to any breach of the above undertakings.</li> <li>The undertaking letter shall remain effective so long as GPC legally and validly exists and GPHL owns controlling interest in GPC.</li> </ol>
Time and period of	The undertaking was given on 29 February 2012 and
undertaking	is valid permanently.
Valid period for performance	N/A
Whether timely and strictly performed	Being performed
Compliance or not	Yes

Item	Content
Background of undertakings	Undertakings related to the Major Assets Reorganization
Party given the undertaking	Controlling shareholder
Details of the undertaking	<ol> <li>After completion of the Major Assets Reorganization, GPHL and its subsidiaries should minimize and regulate connected transactions with new GPC. If there is any unavoidable connected transaction, GPHL and its controlled subsidiaries will sign agreement with new GPC in accordance with laws and perform the legal procedures. They will also fulfill the information disclosure obligations and pursue the reporting and approval procedures according to the requirements of relevant laws and regulations, the Listing Rules of the Shanghai Stock Exchange, the Listing Rules of HKEx and the Articles of Association of Guangzhou Pharmaceutical Company Limited, and warrant that it will not harm the legitimate rights and interests of the subsisting GPC after completion of the Major Assets Reorganization and its other shareholders.</li> <li>The undertaking letter will remain effective so long as GPC legally and validly exists and GPHL owns controlling interest in GPC.</li> </ol>
Time and period of the undertaking	The undertaking was given on 29 February 2012 and is valid permanently.
Valid period for performance	N/A
Whether timely and strictly performed	Being performed
Compliance or not	Yes

Item	Content
Background of the undertakings	Undertakings related to Major Assets Reorganization
Party given the undertaking	Controlling shareholder, the Company
Details of the undertaking	GPHL and the Company mutually undertake as follows in relation to the transactions under the Trademark Custody Agreement between Guangzhou Pharmaceutica Company Limited and Guangzhou Pharmaceutica Holdings Limited (the "Agreement"):
	1. Both parties will enter into a supplemental agreemen ("Supplemental Agreement") to the Agreement as soon as possible after the Agreement becoming effective and before they enter into the first new or renewal licensing agreement relating to the licensing of Wang Lao Ji trademarks in custody under the Agreement, with the specific arrangement for new renewal trademark license to be negotiated by the parties separately. Both parties also agreed that the Supplemental Agreement shall
	<ul> <li>(i) embody the requirement for GPHL to pay the Company a basic custody fee of RMB1 million per year as set out in the Agreement; and</li> </ul>
	<ul><li>(ii) specify that 20% of the new licenses fees will be the custody income for the Company and the remaining 80% will be retained by GPHL</li></ul>
	2. Both parties further undertake that the Supplemental Agreement they entered into in the future under the above arrangement will comply with applicable provisions of the Listing Rules of HKEx and SSI (including but not limited to the requirements of Chapter 14A of the Listing Rules of HKEx and Chapter 10 of the Listing Rules of SSE relating to continuing connected transactions/connected transactions in the ordinary course of business including that the Supplemental Agreement must specify its validity term, the estimated annual cap of custody income, other terms that must be set out and etc.).
Time and period of the undertaking	Commitment made on 26 March 2012 and the period of validity is up to the date of completion of the undertakings
Valid period for performance	N/A
Whether timely and strictly performed	Being performed
Compliance or not	Yes

# 3.3.5 Undertakings related to trademark custodianship

Item	Content
Background of the undertakings	Undertakings related to Major Assets Reorganization
Party given the undertaking	Controlling shareholder
Details of the undertaking	1. GPHL will promote the development of the subsisting listed company, protect the interests of minority investors, and proactively take measures to solve the issue of Baiyunshan properties with legal defects in titles to ensure that the interests of the subsisting listed company and investors are not jeopardised.
	2. Guaranteeing that the subsisting listed company will be able to continue occupying and using such properties after completion of the merger and that it will not incur any additional cost nor suffer any material adverse impact due to such issue.
	3. After completion of the merger, GPHL will fully compensate the Company within 2 months from the date of incurring of the actual losses (not including the tax normally incurred in respect of changing the registration name and transfer in relation to the properties and the land premium in relation to the changes from non-granted land use rights to granted land-use rights) in case there are any penalties imposed on or losses incurred by the Company due to the legal defects in the building ownership or land use rights of the Baiyunshan properties to be acquired by the Company, and such losses include but not limited to all economic losses in connection with any civil, administration and criminal liabilities, to ensure that the Company and minority investors will not suffer any damage thereunder.
Time and period of the undertaking	The undertaking was given on 29 February 2012 and is valid permanently.
Valid period for performance	N/A
Whether timely and strictly performed	Being performed
Compliance or not	Yes

# 3.3.6 Undertakings related to properties with legal defects

Item	Content
Background of the undertakings	Undertakings related to the Major Assets Reorganization
Party given the undertaking	Controlling shareholder
Details of the undertaking	1. GPHL undertakes that, within two years from the date of satisfaction of any one of the conditions set out below, it will legally transfer the trademarks in Wang Lao Ji series (25 in total) and 4 other trademarks (comprising trademarks with registration numbers of 125321, 214168, 538308 and 5466324) to the Company according to the requirements of laws and regulations then in force: (i) Upon the expiry on 1 May 2020, or earlier when the license agreement and its supplemental agreement were invalidated/void/terminated as determined by the arbitration institution, or earlier when the agreement was terminated or released as agreed between the parties; or (ii) Hung To (Holdings) Company Limited (鴻道(集團)有限公司) legally ceases to own the right of pre-emption
	2. On the basis of the original undertaking letter, GPHL has further made the promise as follows: After all of the legal disputes regarding the trademark of Wang Lao Ji have been resolved and within two years commencing from the transferable day, GPHL shall, pursuant to the provisions of the effective laws and regulations then and after the relevant procedures regarding the reporting for approval have been processed, legally transfer to the Company such 29 trademarks of the series of "Wang Lao Ji" together with such other trademarks related to Wang Lao Ji and 4 trademarks obtained and owned in legal manner by GPHL after the Execution Day (inclusive of today) for the "Supplementary Agreement to the Agreement of Trademark Custody". The Company may obtain such by cash or by issuing shares for purchasing assets wherein the transfer price shall be legally confirmed based on such appraisal value as issued by an appraisal institute possessing the professional qualification of engaging in securities and as confirmed in the asset appraisal report verified by the State-owned assets authority.
Time and period of the undertaking	The original undertaking was given on 29 February 2012. GPHL gave a supplemental undertaking in respect of the relevant contents on 15 June 2012. The undertaking remains valid until it has been fully performed.

Item	Content
Valid period for performance	N/A
Whether timely and strictly performed	In December 2014, the Company received the Letter of Amendment to the Undertakings of Injection of Wang Lao Ji Trademark Series from GPHL, which proposed to amend the performance period of the former undertakings to "two years since the commencing date of the judgment on the law case of red can decoration", due to the disputes of red can decoration. As approved at the 8th meeting of the sixth session of the Board, the resolution on the amendment to the performance period of injection of Wang Lao Ji trademark series was
	submitted to the first extraordinary general meeting in 2015 held on 13 March 2015 and was approved.
Compliance or not	Yes

Save as disclosed above, there is no outstanding undertaking that requires specific disclosure.

3.4 Warning and explanation for negative impact on profit in respect of the beginning of 2017 up to the next reporting period, or significant changes in profits in comparison to the corresponding period of 2016

 $\Box$  Applicable  $\checkmark$  Not applicable

**3.5** Explanation on changes in the scope of consolidation as compared with the most recent financial report

 $\Box$  Applicable  $\checkmark$  Not applicable

# 4. APPENDIX

### 4.1 Financial Report

#### **Consolidated Balance Sheet**

As at 31 March 2017

Items	At the end of the Reporting Period (RMB)	At the beginning of 2017 ( <i>RMB</i> )
Current assets:		
Cash at bank and on hand	13,405,852,966.48	13,091,007,880.23
Settlement provisions	-	_
Placements	_	_
Financial assets based on fair value to confirm		
profit or loss	5,752,643.83	6,026,123.94
Derivative financial assets	_	_
Notes receivable	2,177,650,110.48	1,604,767,885.21
Accounts receivable	1,008,390,760.87	1,108,363,607.29
Advances to suppliers	258,799,244.55	414,073,610.15
Premiums receivable	-	_
Receivables from reinsurers	-	_
Reinsurance contract reserve	-	_
Interest receivable	-	_
Dividend receivable	47,938,523.45	52,938,523.45
Other receivables	218,128,008.93	205,120,876.85
Financial assets purchased under resale agreements	_	_
Inventories	2,836,593,826.47	2,781,495,711.45
Classified as assets held for sale	_	_
Current portion of non-current assets	_	_
Other current assets	176,214,685.97	250,191,094.03
Total current assets	20,135,320,771.03	19,513,985,312.60

Items	At the end of the Reporting Period (RMB)	At the beginning of 2017 ( <i>RMB</i> )
Non-currents assets:		
Entrusted loans and advances	_	_
Available-for-sale financial assets	329,367,457.80	327,889,324.24
Held-to-maturity investments	-	_
Long-term receivables	-	_
Long-term equity investment	2,374,811,766.08	2,290,443,462.70
Investments properties	227,155,776.57	228,575,391.31
Fixed assets	2,074,900,596.81	2,107,109,957.69
Construction in progress	261,116,408.21	255,276,101.16
Construction materials	-	_
Disposal of fixed assets	-	_
Production of biological assets	-	_
Oil and gas assets	-	_
Intangible assets	700,655,165.37	668,305,151.10
Development costs	2,017,046.84	3,017,046.84
Goodwill	11,499,562.74	11,499,562.74
Long-term prepaid expenses	43,030,979.05	37,939,444.42
Deferred tax assets	419,843,485.22	417,159,182.77
Other non-current assets		35,970,282.97
Total non-current assets	6,444,398,244.69	6,383,184,907.94
Total assets	26,579,719,015.72	25,897,170,220.54

Items	At the end of the Reporting Period (RMB)	At the beginning of 2017 ( <i>RMB</i> )
Current liabilities:		
Short-term borrowings	19,120,751.12	25,215,424.88
Borrowings from central banks	-	_
Deposits and deposits by banks	-	_
Funds borrowed	-	_
Financial liabilities at fair value through		
profit or loss Derivative financial liabilities	_	_
Notes payable	212,358,945.88	320,811,521.98
Accounts payable	2,448,461,862.36	2,267,279,067.87
Advances from customers	1,431,511,078.85	1,552,885,731.40
Financial assets sold under repurchase agreements	-	_
Fee and commission payable	-	_
Employee benefits payable	398,783,397.75	546,523,380.87
Taxes payable	417,896,043.02	384,192,155.39
Interests payable	276,263.81	257,658.10
Dividend payable Other payables	57,301,541.02 2,618,226,783.20	57,301,541.02 2,267,981,520.69
Payables to reinsurers	2,010,220,705.20	
Insurance contract	_	_
Brokerage deposits	-	_
Acting underwriting securities	-	_
Classified as liabilities held for sale	-	-
Current portion of non-current liabilities	-	_
Other current liabilities		
Total current liabilities	7,603,936,667.01	7,422,448,002.20
Non-current liabilities:		
Long-term borrowings	33,250,398.87	33,502,083.03
Debentures payable	-	_
Including: Preferred shares	-	_
Sustainable debts	-	-
Long-term payable	20,558,783.65 346,797.94	20,558,783.65 316,733.72
Long-term employee benefits payable Payables for specific projects	16,751,608.75	16,842,773.80
Provisions	59,911,795.68	61,045,873.15
Deferred income	598,487,443.76	612,084,162.58
Deferred tax liabilities	83,464,218.69	76,581,360.14
Other non-current liabilities		
Total non-current liabilities	812,771,047.34	820,931,770.07
Total liabilities - 19 -	8,416,707,714.35	8,243,379,772.27

Items	At the end of the Reporting Period (RMB)	At the beginning of 2017 ( <i>RMB</i> )
Shareholders' equity:		
Share capital	1,625,790,949.00	1,625,790,949.00
Other equity instruments	-	_
Including: Preferred shares	-	_
Sustainable debts	-	_
Capital surplus	9,875,172,584.68	9,875,172,584.68
Less: Treasury shares	-	_
Other comprehensive Income	12,601,628.04	9,788,066.97
Special reserves	-	-
Surplus reserves	1,052,034,418.97	1,052,034,418.97
General risk reserve Undistributed profits	- 5,266,955,854.33	4,782,293,720.24
Total equity attributable to the Shareholders of the parent Company	17,832,555,435.02	17,345,079,739.86
Minority interests	330,455,866.35	308,710,708.41
Total shareholders' equity	18,163,011,301.37	17,653,790,448.27
Total liabilities and shareholders' equity	26,579,719,015.72	25,897,170,220.54

Legal Representative:	Director of the Financial Work:	Manager of Finance Department:
Mr. Li Chuyuan	Mr. Wu Changhai	Ms. Yao Zhizhi

# **Parent Company Balance Sheet** As at 31 March 2017

Items	At the end of the Reporting Period (RMB)	At the beginning of 2017 ( <i>RMB</i> )
Current assets:		
Cash at bank and on hand	7,588,153,038.39	8,358,861,097.11
Financial assets based on fair value to confirm		
profit or loss	5,752,643.83	6,026,123.94
Derivative financial assets	-	_
Notes receivable	840,391,642.86	586,068,682.00
Accounts receivable	279,936,479.61	334,495,199.70
Advances to suppliers	5,886,333.65	6,765,642.36
Interest receivable		
Dividend receivable Other receivables	179,913,959.12 1,537,543,366.69	227,303,087.42 1,497,826,949.82
Inventories	341,693,493.44	350,901,854.94
Classified as assets held for sale		
Current portion of non-current assets	_	_
Other current assets	1,104,772.46	311,191.58
Total current assets	10,780,375,730.05	11,368,559,828.87
Non-currents assets:		
Available-for-sale financial assets	325,594,253.51	324,384,253.51
Held-to-maturity investments	-	-
Long-term receivables	-	_
Long-term equity investment	5,123,762,078.30	4,150,739,999.55
Investments properties	214,626,615.30	216,673,097.32
Fixed assets	489,035,719.60	492,475,829.83
Construction in progress	12,138,931.08	10,418,008.58
Construction materials	-	_
Fixed assets pending for disposal	-	_
Production of biological assets Oil and gas assets	-	—
Intangible assets	375,579,062.10	376,892,173.85
Development costs	1,217,046.84	2,217,046.84
Goodwill		
Long-term prepaid expenses	2,186,136.81	2,303,114.09
Deferred tax assets	58,199,543.56	58,199,543.56
Other non-current assets		
Total non-current assets	6,602,339,387.10	5,634,303,067.13
Total assets - 21 -	17,382,715,117.15	17,002,862,896.00

Items	At the end of the Reporting Period (RMB)	At the beginning of 2017 ( <i>RMB</i> )
Current liabilities:		
Short-term borrowings	164,431,644.92	184,431,644.92
Financial liabilities based on fair value		
to confirm profit or loss	-	_
Derivative financial liabilities	-	_
Notes payable	-	-
Accounts payable	176,896,332.77	189,679,883.62
Advances from customers	38,605,172.48	14,149,991.14
Employee benefits payable	56,163,904.78	55,444,007.49
Taxes payable	111,803,148.98	84,161,748.85
Interests payable	-	-
Dividend payable	224,299.47	224,299.47
Other payables	683,193,896.35	597,717,008.34
Classified as liabilities held for sale	-	_
Current portion of non-current liabilities	-	-
Other current liabilities		
Total current liabilities	1,231,318,399.75	1,125,808,583.83
Non-current liabilities:		
Long-term borrowings	_	_
Debentures payable	-	_
Including: Preferred shares	-	_
Sustainable debts	-	_
Long-term payable	7,802,224.39	7,802,224.39
Long-term employee benefits payable	-	_
Payables for specific projects	-	_
Provisions	118,672,495.19	98,550,055.19
Deferred income	75,610,639.73	74,971,856.94
Deferred tax liabilities	4,063,555.02	4,063,555.02
Other non-current liabilities		
Total non-current liabilities	206,148,914.33	185,387,691.54
Total liabilities	1,437,467,314.08	1,311,196,275.37

Items	At the end of the Reporting Period	At the beginning of 2017
	(RMB)	(RMB)
Shareholders' equity:		
Share capital	1,625,790,949.00	1,625,790,949.00
Other equity instruments	-	_
Including: Preferred shares	-	-
Sustainable debts	-	-
Capital surplus	9,820,175,495.89	9,820,175,495.89
Less: Treasury shares	-	-
Other comprehensive Income	12,397,421.73	11,187,421.73
Special reserves	-	-
Surplus reserves	679,425,984.37	679,425,984.37
Undistributed profits	3,807,457,952.08	3,555,086,769.64
Total shareholders' equity	15,945,247,803.07	15,691,666,620.63
Total liabilities and shareholders' equity	17,382,715,117.15	17,002,862,896.00

Legal Representative:	Director of the Financial Work:	Manager of Finance Department:
Mr. Li Chuyuan	Mr. Wu Changhai	Ms. Yao Zhizhi

# Consolidated Income Statement

Items	1 January – 31 March 2017 ( <i>RMB</i> )	1 January – 31 March 2016 ( <i>RMB</i> )
1. Revenue	5,287,931,179.78	5,050,888,725.01
Including: Income from operations	5,287,931,179.78	5,050,888,725.01
Interest Income	_	_
Premiums earned	-	_
Fee and commission income	-	-
2. Total cost from operations	4,814,504,806.76	4,649,878,463.66
Including: Cost of operations	3,206,010,323.47	3,049,994,401.19
Interest expense	-	_
Fee and commission expense	-	_
Surrenders	-	-
Net claims paid	-	-
Net reserves for insurance contracts	-	_
Policyholder dividends	-	_
Reinsurance expenses	-	-
Taxes and surcharges	57,108,153.61	45,979,906.73
Selling and distribution expenses	1,210,938,902.50	1,188,453,821.58
General and administrative expenses Financial expenses	371,559,833.11 (28,074,787.65)	369,699,372.01 (9,350,337.05)
Asset impairment losses	(3,037,618.28)	5,101,299.20
Add: Profit arising from the changes	(3,037,010.20)	5,101,299.20
in fair value	(273,480.11)	(1,012,684.70)
Investment income	90,476,652.44	93,590,025.16
Including: Share of profits from associates and	> 0, 17 0,002111	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
jointly controlled entities	90,476,652.54	93,590,025.16
Exchange gains	_	_
3. Operating profit	563,629,545.35	493,587,601.81
Add: Non-operating income	46,573,407.39	35,677,709.29
Including: Gain on disposal of Non-current assets	10,800.00	190,261.65
Less: Non-operating expenses	20,342,643.73	15,457,788.14
Including: Losses from disposal of non-current		
assets	376,233.00	321,677.06
4. Total profit	589,860,309.01	513,807,522.96
Less: Income tax expense	86,403,748.46	90,109,683.44
5. Net profit	503,456,560.55	423,697,839.52
<b>r</b>		,
Net profit attributable to the shareholders		
of the Company	484,662,134.09	409,318,579.16
Minority interests	18,794,426.46	14,379,260.36

Items	1 January – 31 March 2017 ( <i>RMB</i> )	1 January – 31 March 2016 ( <i>RMB</i> )
<ul> <li>6. After-tax net income of other comprehensive income</li> <li>After-tax net income of other comprehensive income attributable to the parent company</li> </ul>	2,824,292.54	(512,712.12)
owner Items will not be classified into profit or loss when satisfied with certain conditions at	2,813,561.07	(507,475.17)
<ul><li>following accounting period</li><li>(1) Changes as a result of remeasurement of net defined benefit plan liability or asset</li></ul>	-	
<ul><li>(2) Portion of items will not be classified into profit or loss when under equity method Items will be classified into profit or loss when</li></ul>	-	_
satisfied with certain conditions at following accounting period	2,813,561.07	(507,475.17)
<ol> <li>Portion of items will be classified into profit or loss when under equity method</li> <li>Profit or loss arising from changes in fair</li> </ol>	181,500.00	49,858.17
<ul><li>value of available for sale financial assets</li><li>(3) Profit or loss arising from reclassification of held to maturity investments as available</li></ul>	1,230,175.70	(635,126.69)
<ul><li>for sale financial assets</li><li>(4) The effective hedging portion of profit or loss arising from cash flow hedging instruments</li></ul>	-	_
<ul> <li>(5) Differences arising from translation of foreign currency financial statements</li> <li>(6) Others</li> </ul>	- 1,401,885.37 -	77,793.35
After-tax net income of other comprehensive income attributable to minority shareholders equity	10,731.47	(5,236.95)
7. Total comprehensive income	506,280,853.09	423,185,127.40
Total comprehensive income attributable to the shareholders of the Company Comprehensive income attributable to the	487,475,695.16	408,811,103.99
shareholders of minority shareholder's equity	18,805,157.93	14,374,023.41
<ul> <li>8. Earnings per share</li> <li>(1) Basic earnings per share</li> <li>(2) Diluted earnings per share</li> </ul>	0.298 0.298	0.317 0.317
Legal Representative: Director of the Financial Work	: Manager of Fin	nance Department:

	Legar Representative.	Director of the I manetal work.	manager of I manee
Mr. Li Chuyuan Mr. Wu Changhai Ms. Yao Zhizhi	Mr. Li Chuyuan	Mr. Wu Changhai	Ms. Yao Zhizhi

# Income Statement of the Parent Company

Items	1 January – 31 March 2017 <i>(RMB)</i>	1 January– 31 March 2016 ( <i>RMB</i> )
1. Revenue	825,088,123.11	758,962,617.27
Less: Cost of sales	368,776,099.36	345,826,820.57
Taxes and surcharges	14,162,212.15	12,906,292.05
Selling and distribution expenses	147,137,363.00	136,689,676.26
General and administrative expenses	104,352,472.57	93,141,402.23
Financial expenses	(11,514,445.24)	2,284,146.93
Asset impairment losses	(814,185.69)	(1,150,390.56)
Add: Profit arising from the changes in fair value	(273,480.11)	(1,012,684.70)
Investment income	77,751,578.65	78,137,908.09
Including: Share of profits from associates and		
jointly controlled entities	77,751,578.75	78,137,908.09
2. Operating profit	280,466,705.50	246,389,893.18
Add: Non-operating income	2,844,439.14	9,828,595.69
Including: Gains on disposal of Non-current assets	800.00	-
Less: Non-operating expenses	622,510.59	595,081.84
Including: Losses from disposal of non-current		
assets	115,079.05	_
3. Total profit	282,688,634.05	255,623,407.03
Less: Income tax expenses	30,317,451.61	22,322,513.99
4. Net profit	252,371,182.44	233,300,893.04

Items	1 January – 31 March 2017 ( <i>RMB</i> )	1 January– 31 March 2016 ( <i>RMB</i> )
5. Other comprehensive income	1,210,000.00	(2,469,966.83)
Items will not be classified into profit or loss		
when satisfied with certain conditions at		
following accounting period	-	_
(1) Changes as a result of remeasurement of net		
defined benefit plan liability or asset	-	-
(2) Portion of items will not be classified into		
profit or loss when under equity method	-	_
Items will be classified into profit or loss when		
satisfied with certain conditions at following accounting period	1,210,000.00	(2,469,966.83)
(1) Portion of items will be classified into	1,210,000.00	(2,409,900.03)
profit or loss when under equity method	181,500.00	49,858.17
(2) Profit or loss arising from changes in	101,00000	.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
fair value of available for sale		
financial assets	1,028,500.00	(2,519,825.00)
(3) Profit or loss arising from reclassification		
of held to maturity investments as		
available for sale financial assets	-	_
(4) The effective hedging portion of profit		
or loss arising from cash flow		
hedging instruments	-	—
(5) Differences arising from translation of		
foreign currency financial statements (6) Others	-	_
6. Total comprehensive income	- 253,581,182.44	230,830,926.21
0. Total comprehensive income	255,501,102.44	250,850,920.21
7. Earnings per share		
(1) Basic earnings per share	_	_
(2) Diluted earnings per share	_	_

Legal Representative:	Director of the Financial Work:	Manager of Finance Department:
Mr. Li Chuyuan	Mr. Wu Changhai	Ms. Yao Zhizhi

# Consolidated Cash Flow Statement

Items	1 January – 31 March 2017 ( <i>RMB</i> )	1 January – 31 March 2016 ( <i>RMB</i> )
<ol> <li>Cash flows from operating activities         Cash received from sale of goods and rendering             of services         Customer deposits and interbank net increase             in deposits         </li> </ol>	3,969,964,906.47	3,791,194,321.87
Net increase in borrowings from central banks Borrowing funds from other financial institutions	-	-
Net increase Receipt of the original insurance contract cash Net cash received from reinsurance business Net increase in policyholders' deposits and investments	-	
Net increase of disposal of trading financial assets Charge interest, fees and commissions Net increase of capital borrowed Net increase in repo operations funds	- - - -	- - - -
Refund of taxes and surcharges Cash received relating to other operating activities	2,210,315.43 122,569,936.11	2,178,759.92 598,174,630.20
Sub-total of cash inflows	4,094,745,158.01	4,391,547,711.99
Cash paid for goods and services Net increase in loans and advances to customers Central banks and interbank deposits Cash Pay the original insurance contract paid in cash Payment of interest, fees and commissions Policyholder dividends paid in cash Cash paid to and on behalf of employees Payments of taxes and surcharges	1,740,733,812.71 - - - - 970,832,981.29 438,382,743.52	1,830,956,193.14 - - - 894,521,101.86 349,315,570.41
Cash paid relating to other operating activities	718,825,468.09	573,488,786.99
Sub-total of cash outflows	3,868,775,005.61	3,648,281,652.40
Net cash flows from operating activities	225,970,152.40	743,266,059.59
2. Cash flows from investing activities Cash received from disposal of investments Cash received from returns on investments Net cash received from disposal of fixed assets, intangible assets and other long-term assets Net cash received from sales of subsidiaries Cash received from other investing activities	- 15,000,000.00 5,391.37 - 631,643.85	_  224,656.70 _ _
Sub-total of cash inflows	15,637,035.22	224,656.70

Items	1 January – 31 March 2017 ( <i>RMB</i> )	1 January – 31 March 2016 ( <i>RMB</i> )
Cash paid to acquire fixed assets, intangible assets and other long-term assets Cash paid to acquire investments Net increase in loans Net cash paid for acquire subsidiaries	28,912,425.44 _ _ _	54,463,306.06 50,000,000.00 
Cash paid relating to other investing activities	-	824,259.41
Sub-total of cash outflows	28,912,425.44	105,287,565.47
Net cash flows from investing activities	(13,275,390.22)	(105,062,908.77)
<b>3. Cash flows from financing activities</b> Cash received from capital contributions Including: Cash received from capital contributions by minority	2,940,000.00	100,000.00
shareholders to subsidiaries Cash received from borrowings Cash received from issuance of bonds Cash received relating to other financing activities	2,940,000.00	100,000.00 164,381,864.77 
Sub-total of cash inflows	2,940,000.00	164,481,864.77
Cash repayments of borrowings Cash payments for interest expenses and distribution of dividends or profits Including: Cash payments for dividends or profit to minority shareholders of subsidiaries	- 1,248,709.56	208,202,012.18 6,703,336.37 685.59
Cash payments relating to other financing activities	_	135,783.68
Sub-total of cash outflows	1,248,709.56	215,041,132.23
Net cash flows from financing activities	1,691,290.44	(50,559,267.46)
4. Effects of foreign exchange rate changes on cash and cash equivalents	(110,523.49)	60,481.93
5. Net increase in cash and cash equivalents	214,275,529.13	587,704,365.29
Add: Cash and cash equivalents at the beginning of the period	12,756,469,786.51	3,837,603,553.99
6. Cash and cash equivalents at the end of the period	12,970,745,315.64	4,425,307,919.28
Legal Representative:Director of the Financial Work:Manager of Finance Department:Mr. Li ChuyuanMr. Wu ChanghaiMs. Yao Zhizhi		

# Cash Flow Statement of the Parent Company

Items	1 January– 31 March 2017 ( <i>RMB</i> )	1 January– 31 March 2016 ( <i>RMB</i> )
<ol> <li>Cash flows from operating activities         Cash received from sale of goods and rendering of services         Refund of taxes and surcharges     </li> </ol>	305,361,994.89	385,566,667.59
Cash received relating to other operating activities	43,220,157.25	126,880,954.78
Sub-total of cash inflows	348,582,152.14	512,447,622.37
Cash paid for goods and services Cash paid to and on behalf of employees Payments of taxes and surcharges Cash paid relating to other operating activities	67,471,609.18 115,084,472.37 98,316,486.75 37,678,045.40	77,813,586.16 168,160,421.47 88,767,324.54 71,569,142.92
Sub-total of cash outflows	318,550,613.70	406,310,475.09
Net cash flows from operating activities	30,031,538.44	106,137,147.28
2. Cash flows from investing activities Cash received from disposal of investments Cash received from returns on investments Net cash received from disposal of fixed assets, intangible assets and other long-term assets Net cash received from sales of subsidiaries	_ 108,029,087.62 _ _	 33,241,189.47 
Cash received from other investing activities	255,810,472.70	190,802,823.53
Sub-total of cash inflows	363,839,560.32	224,044,013.00
Cash paid to acquire fixed assets, intangible assets and other long-term assets Cash paid to acquire investments Net cash paid for acquire subsidiaries Cash paid relating to other investing activities	5,858,653.19 895,270,500.00 - 242,000,000.00	1,665,856.56 121,500,000.00 - 182,690,994.34
Sub-total of cash outflows	1,143,129,153.19	305,856,850.90
Net cash flows from investing activities	(779,289,592.87)	(81,812,837.90)

Items	1 January– 31 March 2017 ( <i>RMB</i> )	1 January– 31 March 2016 ( <i>RMB</i> )
3. Cash flows from financing activities Cash received from capital contributions Cash received from borrowings Cash received relating to other financing activities Sub-total of cash inflows	- - -	_ 30,000,000.00 _ 30,000,000.00
Cash repayments of borrowings Cash payments for interest expenses and distribution of dividends or profits Cash payments relating to other financing activities	20,000,000.00 1,540,755.31 –	30,000,000.00 778,166.67 3,383,577.21
Sub-total of cash outflows Net cash flows from financing activities	21,540,755.31 (21,540,755.31)	34,161,743.88
4. Effects of foreign exchange rate changes on cash and cash equivalents	9.58	
<b>5. Net increase in cash and cash equivalents</b> Add: Cash and cash equivalents at the beginning of the period	(770,798,800.16) 8,326,923,391.07	20,162,565.50 960,889,437.00
6. Cash and cash equivalents at the end of the period	7,556,124,590.91	981,052,002.50

Legal Representative:	Director of the Financial Work:	Manager of Finance Department:
Mr. Li Chuyuan	Mr. Wu Changhai	Ms. Yao Zhizhi

#### 4.2 Audited Report

 $\Box$  Applicable  $\checkmark$  Not applicable

### The Board of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 26 April 2017

As at the date of this report, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Chu Xiaoping and Mr. Jiang Wenqi as independent non-executive directors.